


<!DOCTYPE html>
<html lang="en">
<head>  

        <title>Screening and Diagnosis of Obstructive Sleep Apnea | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="51029.html#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="../../../www.googletagmanager.com/ns.html%3Fid=GTM-W4NX5V.html"
                height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="../../../www.googletagmanager.com/ns.html%3Fid=GTM-KHDP6Z.html"
                height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="51029.html#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="51029.html#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="51029.html#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source
				            media="(min-width: 960px)"
				            srcset="/UI/images/logo_NGC_header.png">
				        <source
				            srcset="/UI/images/logo_NGC_header_m.png">
				        <img
				            src="https://www.guideline.gov/UI/images/logo_NGC_header.png"
				            alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In" />
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline&#32;Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class='content'><div class='fundingNotice2'><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href='https://www.guideline.gov/home/announcements'>full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

	<!-- CONTENT HEADER -->
	<div class="content-header">
		<ul class="content-header-meta">
			<li class="prefix-icon large-icon synthesis">Guideline Synthesis</li>
		</ul>
		<h1>Screening and Diagnosis of Obstructive Sleep Apnea</h1>
	</div><!-- /.content-header -->

	<!-- COMPARED LIST-->
		<p>Guidelines Being Compared:</p>
		<ul class="compared-list"> 
				<li>
                    <p class="compared-list-org">American Academy of Sleep Medicine (AASM)</p>
					<p class="compared-list-title">Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline.</p>
                    <p class="compared-list-org">2017 Mar 15</p>
					<p><a class="prefix-icon guideline" href="https://www.guideline.gov/summaries/summary/50887">View Summary</a></p>					
				</li>
				<li>
                    <p class="compared-list-org">American College of Physicians (ACP)</p>
					<p class="compared-list-title">Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians</p>
                    <p class="compared-list-org">2014 Aug 05</p>
					<p><a class="prefix-icon guideline" href="https://www.guideline.gov/summaries/summary/48429">View Summary</a></p>					
				</li>
		</ul><!-- /.compared-list -->
			
	<!-- TOOLBAR -->
	<div class="content-toolbar">
		<!-- Primary -->
		<ul class="tools primary-tools">
			<li class="dropdown tool sections">
				<a href="51029.html#" class="tool-button">Sections</a>
				<div class="dropdown-panel">
						<ul class="section-links">
								<li><a href="51029.html#504" class="section-mark">Areas of Agreement and Difference</a></li>
								<li><a href="51029.html#505" class="section-mark">Comparison of Recommendations</a></li>
								<li><a href="51029.html#506" class="section-mark">Strength of Evidence and Recommendation Grading Schemes</a></li>
								<li><a href="51029.html#507" class="section-mark">Methodology</a></li>
								<li><a href="51029.html#509" class="section-mark">Benefits and Harms</a></li>
								<li><a href="51029.html#511" class="section-mark">Abbreviations</a></li>
								<li><a href="51029.html#512" class="section-mark">Status</a></li>
						</ul>    
				</div><!-- /.dropdown-panel -->
			</li>
		</ul><!-- /.tools primary-tools -->

		<!-- Other -->
		<ul class="tools other-tools">
			<li class="dropdown tool">
				<a href="51029.html#" class="tool-button">Share</a>
				<div class="dropdown-panel">
					<ul class="toolbar-social">
						<li><a target="_blank" href="https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/syntheses/synthesis/51029" class="facebook">Facebook</a></li>
						<li><a target="_blank" href="https://twitter.com/share?text=&url=https://www.guideline.gov/syntheses/synthesis/51029" class="twitter">Twitter</a></li>
						<li><a target="_blank" href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.guideline.gov/syntheses/synthesis/51029&title=&summary=&source="  class="linkedin">Linkedin</a></li>
						<li><a href="mailto:?Subject=AHRQ: Screening and Diagnosis of Obstructive Sleep Apnea&body=https://www.guideline.gov/syntheses/synthesis/51029" class="email">Email</a></li>
					</ul><!-- /.toolbar-social -->
				</div><!-- /.dropdown-panel -->
			</li>
			<li class="dropdown tool">
				<a href="51029.html#" class="tool-button">Cite</a>
				<div class="dropdown-panel citation">
				    <p class="text-label"><label for="citation">Citation: </label></p>
					<textarea id="citation">Internet citation: National Guideline Clearinghouse (NGC). Guideline synthesis: Screening and diagnosis of obstructive sleep apnea. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2017 Jun. [cited YYYY Mon DD]. Available: http://www.guideline.gov.</textarea>
				</div><!-- /.dropdown-panel -->
			</li>
		</ul><!-- /.tools other-tools -->

		<!-- Accordion tools -->
		<ul class="tools accordion-controls">
			<li class="tool"><a href="51029.html#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
			<li class="tool"><a href="51029.html#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
		</ul><!-- /.accordion-controls -->
	</div><!-- /.toolbar -->            

		<!-- ARTICLE -->
		<div class="article" id="article">
			



	<!-- ACCORDION -->
	<div class="accordion-container" role="tablist" multiselectable="true">
			<h2 class="accordion-title is-active" id="504" role="tab" aria-expanded="true" aria-controls="syn504"><a href="51029.html#">Areas of Agreement and Difference</a></h2>
			<div class="accordion-panel is-active" id="syn504" role="tabpanel" aria-labelledby="504" ><a name="areasofagreementanddifference"></a>
<p>A direct comparison of recommendations presented in the above guidelines for the screening and diagnosis of obstructive sleep apnea (OSA) in adults is provided.</p>
<h3><a name="agreement"></a>Areas of Agreement</h3>
<h4>Diagnosis of OSA in Adults with Comorbid Conditions</h4>
<p>The guideline developers agree that polysomnography should be used to diagnose OSA in patients with comorbid conditions. The AASM makes a <strong>strong</strong> recommendation against the use of HSAT in adults with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep-related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia in order to diagnose OSA. The ACP makes a weak recommendation based on moderate-quality evidence for the first-line use of polysomnography for diagnostic testing in patients with suspected OSA, and if polysomnography is not available, portable sleep monitors are an appropriate alternative in patients without serious comorbidities. The ACP also notes that the utility of portable monitors for patients with serious comorbid conditions, including chronic lung disease, congestive heart failure, or neurologic disorders, has not been verified because most available studies excluded these patients.</p>
<h4>Questionnaires and Clinical Prediction Rules/Algorithms</h4>
<p>The AASM makes a <strong>strong</strong> recommendation against the use of these tools in the absence of polysomnography or HSAT. The ACP does not make a recommendation for or against the use of these tools and notes that while sleepiness questionnaires, such as the Epworth Sleepiness Scale (ESS), help in assessing the symptom severity of OSA they cannot assess the AHI (a necessary but not sufficient component of OSA) and lack sufficient sensitivity and specificity to replace a sleep study in diagnosing OSA. While there is low-quality evidence suggesting that some clinical prediction rules can be used to effectively predict OSA diagnosis, the applicability of these rules to the general population cannot be determined from the existing literature, adds the ACP.</p>
<h3><a name="difference"></a>Areas of Difference</h3>
<h4>Screening</h4>
<p>The ACP recommends that clinicians target their assessment of OSA to individuals with unexplained daytime sleepiness, the clinically relevant OSA symptom most responsive to treatment. Additional common presenting symptoms cited by the developer include unintentional sleep episodes during wakefulness, unrefreshing sleep, fatigue, insomnia, and snoring; the best documented risk factor for OSA is obesity. If other causes have been ruled out, further evaluation may be warranted in patients with daytime sleepiness, states the ACP.</p>
<p>The AASM, in contrast, recommends diagnostic testing in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA, defined as the presence of excessive daytime sleepiness and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension. The developer defines an uncomplicated patient as the absence of the following: conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing; concern for significant non-respiratory sleep disorder(s) that require evaluation; and environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT.</p>
<h4>Diagnostic Testing in Uncomplicated Adults</h4>
<p>The AASM and the ACP agree that polysomnography is considered the reference standard for diagnostic testing in uncomplicated adult patients with suspected OSA. Both guideline developers also address the use of home sleep apnea testing (HSAT) with portable sleep monitors. With regard to which of the two methods is preferred, the ACP makes a <strong>weak</strong> recommendation based on moderate-quality evidence for the first-line use of polysomnography for diagnostic testing in patients with suspected OSA. If polysomnography is not available, portable sleep monitors are an appropriate alternative in patients without serious comorbidities, states the ACP.</p>
<p>The AASM makes a <strong>strong</strong> recommendation for the use of <span style="text-decoration: underline;">either</span> polysomnography or HSAT with a technically adequate device in patients for whom diagnostic testing is planned. If HSAT is selected for initial testing and the test is negative, inconclusive or technically inadequate, polysomnography should be performed to establish a diagnosis of OSA, recommends the AASM.</p>
<p>The AASM defines a technically adequate portable sleep monitoring device as one that incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or peripheral arterial tonometry (PAT) with oximetry and actigraphy. The test should include a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period, adds the AASM. According to the ACP, direct evidence from studies comparing one monitor with another is lacking. Monitors with more channels perform better than those with fewer channels, adds the developer, and type IV monitors have an important limitation in that they are unable to distinguish obstructive from central sleep apnea.</p></div>
			<h2 class="accordion-title is-active" id="505" role="tab" aria-expanded="true" aria-controls="syn505"><a href="51029.html#">Comparison of Recommendations</a></h2>
			<div class="accordion-panel is-active" id="syn505" role="tabpanel" aria-labelledby="505" ><table width="100%" border="1" cellspacing="1" cellpadding="8" summary="Table: Provides a comparison of recommendations considered by each group">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top">AASM<br />
            (2017)</th>
            <td valign="top" style="width: 90%;">
            <p>The following are good practice statements, the implementation of which is deemed necessary for appropriate and effective diagnosis and management of OSA.</p>
            <ul style="list-style-type: disc;">
                <li>Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up. </li>
                <li>Polysomnography is the standard diagnostic test for the diagnosis of OSA in adult patients in whom there is a concern for OSA based on a comprehensive sleep evaluation. </li>
            </ul>
            <p><strong><span style="text-decoration: underline;">Diagnosis of OSA in Adults Using Clinical Tools, Questionnaires and Prediction Algorithms</span></strong></p>
            <p><strong>Recommendation 1</strong>: The Task Force (TF) recommends that clinical tools, questionnaires and prediction algorithms not be used to diagnose OSA in adults, in the absence of polysomnography or home sleep apnea testing. (<strong>Strong</strong>)</p>
            <p><strong><span style="text-decoration: underline;">HSAT for the Diagnosis of OSA in Adults</span></strong></p>
            <p><strong>Recommendation 2</strong>: The TF recommends that polysomnography, or home sleep apnea testing (HSAT) with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA. (<strong>Strong</strong>)</p>
            <p><strong>Recommendation 3</strong>: The TF recommends that if a single home sleep apnea test is negative, inconclusive or technically inadequate, polysomnography be performed for the diagnosis of OSA. (<strong>Strong</strong>)</p>
            <p><em>Remarks</em>: The following remarks are based on specifications used by studies that support these recommendation statements:</p>
            <p>An uncomplicated patient is defined by the absence of:</p>
            <ol style="list-style-type: decimal;" start="1">
                <li>Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation and sleep related hypoxemia). Examples of these conditions include significant cardiopulmonary disease, potential respiratory muscle weakness due to neuromuscular conditions, history of stroke and chronic opiate medication use. </li>
                <li>Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia). </li>
                <li>Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT. </li>
            </ol>
            <p>An increased risk of moderate to severe OSA is indicated by the presence of excessive daytime sleepiness and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension.</p>
            <p>HSAT is to be administered by an accredited sleep center under the supervision of a board-certified sleep medicine provider.</p>
            <p>A single HSAT recording is conducted over at least one night.</p>
            <p>A technically adequate HSAT device incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or else peripheral arterial tonometry (PAT) with oximetry and actigraphy. For additional information regarding HSAT sensor requirements, refer to <em>The American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events</em>.</p>
            <p>A technically adequate diagnostic test includes a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period.</p>
            <p><strong><span style="text-decoration: underline;">Diagnosis of OSA in Adults with Comorbid Conditions</span></strong></p>
            <p><strong>Recommendation 4</strong>: The TF recommends that polysomnography, rather than home sleep apnea testing, be used for the diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep-related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia. (<strong>Strong</strong>)</p>
            <p><strong><span style="text-decoration: underline;">Diagnosis of OSA in Adults Using a Split-Night versus a Full-Night Polysomnography Protocol</span></strong></p>
            <p><strong>Recommendation 5</strong>: The TF suggests that, if clinically appropriate, a split-night diagnostic protocol, rather than a full-night diagnostic protocol for polysomnography be used in the diagnosis of OSA. (<strong>Weak</strong>)</p>
            <p><em>Remarks</em>: Clinically appropriate is defined as the absence of conditions identified by the clinician that are likely to interfere with successful diagnosis and treatment using a split-night protocol.</p>
            <p>This recommendation is based on a split-night protocol that initiates CPAP titration only when the following criteria are met: (1) a moderate to severe degree of OSA is observed during a minimum of 2 hours of recording time on the diagnostic polysomnography, AND (2) at least 3 hours are available for CPAP titration.</p>
            <p><strong><span style="text-decoration: underline;">Repeat Polysomnography for the Diagnosis of OSA in Adults</span></strong></p>
            <p><strong>Recommendation 6</strong>: The TF suggests that when the initial polysomnogram is negative and there is still clinical suspicion for OSA, a second polysomnogram be considered for the diagnosis of OSA. (<strong>Weak</strong>)</p>
            </td>
        </tr>
        <tr>
            <th class="Center" valign="top">ACP<br />
            (2014)</th>
            <td valign="top">
            <p><strong>Recommendation 1</strong>: <em>ACP recommends a sleep study for patients with unexplained daytime sleepiness</em>. (<strong>Grade: weak recommendation, low-quality evidence</strong>)</p>
            <p>Clinicians should target their assessment of OSA to individuals with unexplained daytime sleepiness. This assessment should include evaluation of the risk factors and common presenting symptoms for OSA. The best documented risk factor for OSA is obesity. Clinical symptoms for OSA include unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, and snoring. If other causes have been ruled out (for example, thyroid disease, gastroesophageal reflux disease, or other respiratory diseases), further evaluation for OSA may be warranted in patients with daytime sleepiness, which is the clinically relevant OSA symptom most responsive to treatment. Evidence is lacking on the effect of CPAP on improving other outcomes, including hypertension, diabetes, coronary heart disease events, and mortality, especially among individuals without daytime sleepiness. For guidance on treatment, clinicians should refer to the ACP guideline on management of OSA. Sleepiness questionnaires, such as the Epworth Sleepiness Scale (ESS), help in assessing the symptom severity of OSA but cannot assess the AHI (a necessary but not sufficient component of OSA) and lack sufficient sensitivity and specificity to replace a sleep study in diagnosing OSA.</p>
            <p><strong>Recommendation 2</strong>: <em>ACP recommends polysomnography for diagnostic testing in patients suspected of OSA. ACP recommends portable sleep monitors in patients without serious comorbidities as an alternative to polysomnography when polysomnography is not available for diagnostic testing</em>. (<strong>Grade: weak recommendation, moderate-quality evidence</strong>)</p>
            <p>Full-night, attended, in-laboratory polysomnography is considered the reference standard diagnostic test and is recommended in patients with suspected OSA. However, in the absence of polysomnography, portable monitors may be used as an alternative diagnostic test in such patients. Both the AASM and the Centers for Medicare &amp; Medicaid Services consider an AHI score of at least 15 events per hour or at least 5 events per hour with symptoms (such as daytime somnolence and fatigue) as criteria for OSA diagnosis. Evidence shows that compared with polysomnography, type II, III, and IV monitors have a wide range of difference in AHI estimates. These monitors have a high positive likelihood ratio and low negative likelihood ratio for various AHI cutoff levels to predict OSA. Monitors with more channels perform better than those with fewer channels, and type IV monitors have an important limitation in that they are unable to distinguish obstructive from central sleep apnea. There is no direct evidence from head-to-head comparisons of type III and IV monitors, but indirect evidence from studies comparing each monitor with polysomnography suggested that type III monitors performed better than type IV monitors in predicting AHI scores suggestive of OSA. Although portable monitors may be useful, data loss of 3% to 20% has been reported for type III and IV monitors. Furthermore, inadequate data resulting in limited interpretation of results from the use of type III monitors has been reported for 13% to 20% of the evaluations. The utility of portable monitors for patients with serious comorbid conditions, including chronic lung disease, congestive heart failure, or neurologic disorders, has not been verified.</p>
            <p>Evidence from studies comparing one monitor with another is lacking. The Figure in the original guideline document summarizes the recommendations and clinical considerations.</p>
            </td>
        </tr>
    </tbody>
</table></div>
			<h2 class="accordion-title is-active" id="506" role="tab" aria-expanded="true" aria-controls="syn506"><a href="51029.html#">Strength of Evidence and Recommendation Grading Schemes</a></h2>
			<div class="accordion-panel is-active" id="syn506" role="tabpanel" aria-labelledby="506" ><p><a name="strength"></a></p>
<table width="100%" border="1" cellspacing="1" cellpadding="8" summary="This table presents the rating schemes used by the guideline groups to rate the level of evidence and/or the strength of the recommendations.">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top">AASM<br />
            (2017)</th>
            <td valign="top" style="width: 90%;">
            <p><strong>Quality of a Body of Evidence</strong></p>
            <p><strong>High</strong>: Corresponds to a high level of certainty that the true effect lies close to that of the estimate of the effect.</p>
            <p><strong>Moderate</strong>: Corresponds to a moderate level of certainty in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</p>
            <p><strong>Low</strong>: Corresponds to a low level of certainty in the effect estimate; the true effect may be substantially different from the estimate of the effect.</p>
            <p><strong>Very low</strong>: Corresponds to very little certainty in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.</p>
            <p><strong>Strength of Recommendations</strong></p>
            <p><strong>Strong</strong>: A STRONG recommendation is one that clinicians should, under most circumstances, always follow (i.e., something that might qualify as a Quality Measure).</p>
            <p><strong>Weak</strong>: A WEAK recommendation reflects a lower degree of certainty in the appropriateness of the patient-care strategy and requires that the clinician use his/her clinical knowledge and experience, and refer to the individual patient's values and preferences to determine the best course of action.</p>
            <p><strong>Example Characteristics of AASM Strengths of Recommendations</strong></p>
            <table role="presentation" border="1" cellspacing="1" cellpadding="3" summary="Table: Example Characteristics of American Academy of Sleep Medicine (AASM) Strengths of Recommendations">
                <tbody>
                    <tr>
                        <th class="Center" valign="top" colspan="2">AASM Strength of Recommendation</th>
                        <th class="Center" valign="top">Example Characteristics Guiding Recommendation</th>
                    </tr>
                    <tr>
                        <td class="Center" valign="middle" rowspan="2">FOR</td>
                        <td class="Center" valign="middle">STRONG</td>
                        <td valign="top">
                        <ul style="list-style-type: disc;">
                            <li>There is a high degree of clinical certainty that the balance between benefits vs. harms (i.e., <span style="text-decoration: underline;">net benefits</span>) favors benefits for this patient-care strategy. </li>
                            <li>The vast majority of well-informed patients would most likely choose this patient-care strategy, compared to alternative patient-care strategies or no treatment. </li>
                        </ul>
                        </td>
                    </tr>
                    <tr>
                        <td class="Center" valign="middle">WEAK</td>
                        <td valign="top">
                        <ul style="list-style-type: disc;">
                            <li>There is a lower degree of clinical certainty in the balance between benefits vs. harms (i.e., <span style="text-decoration: underline;">net benefits</span>) favors benefit for this patient-care strategy. </li>
                            <li>The majority of well-informed patients would most likely choose this patient-care strategy, compared to alternative patient-care strategies or no treatment. </li>
                        </ul>
                        </td>
                    </tr>
                    <tr>
                        <td class="Center" valign="middle" rowspan="2">AGAINST</td>
                        <td class="Center" valign="middle">WEAK</td>
                        <td valign="top">
                        <ul style="list-style-type: disc;">
                            <li>There is a lower degree of clinical certainty in the balance between benefits vs. harms (i.e., <span style="text-decoration: underline;">net harms</span>) of this patient-care strategy. </li>
                            <li>The majority of well-informed patients would most likely not choose this patient-care strategy, compared to alternative patient-care strategies or no treatment. </li>
                        </ul>
                        </td>
                    </tr>
                    <tr>
                        <td class="Center" valign="middle">STRONG</td>
                        <td valign="top">
                        <ul style="list-style-type: disc;">
                            <li>There is a high degree of clinical certainty in the balance between benefits vs. harms (i.e., <span style="text-decoration: underline;">net harms</span>) of this patient-care strategy. </li>
                            <li>The vast majority of well-informed patients would most likely not choose this patient-care strategy, compared to alternative patient-care strategies or no treatment. </li>
                        </ul>
                        </td>
                    </tr>
                </tbody>
            </table>
            </td>
        </tr>
        <tr>
            <th width="10%" class="Center" valign="top">ACP<br />
            (2014)</th>
            <td valign="top" style="width: 90%;">
            <p><strong>Grading of Quality of Evidence</strong></p>
            <p><strong>High-Quality Evidence</strong>: Evidence is considered high quality when it is obtained from 1 or more well-designed and well-executed randomized, controlled trials (RCTs) that yield consistent and directly applicable results. This also means that further research is very unlikely to change confidence in the estimate of effect.</p>
            <p><strong>Moderate-Quality Evidence</strong>: Evidence is considered moderate quality when it is obtained from RCTs with important limitations&mdash;for example, biased assessment of the treatment effect, large loss to follow-up, lack of blinding, unexplained heterogeneity (even if it is generated from rigorous RCTs), indirect evidence originating from similar (but not identical) populations of interest, and RCTs with a very small number of participants or observed events. In addition, evidence from well-designed controlled trials without randomization, well-designed cohort or case-control analytic studies, and multiple time series with or without intervention are in this category. Moderate-quality evidence also means that further research will probably have an important effect on confidence in the estimate of effect and may change the estimate.</p>
            <p><strong>Low-Quality Evidence</strong>: Evidence obtained from observational studies would typically be rated as low quality because of the risk for bias. Low-quality evidence means that further research is very likely to have an important effect on confidence in the estimate of effect and will probably change the estimate. However, the quality of evidence may be rated as moderate or even high, depending on circumstances under which evidence is obtained from observational studies. Factors that may contribute to upgrading the quality of evidence include a large magnitude of the observed effect, a dose-response association, or the presence of an observed effect when all plausible confounders would decrease the observed effect.</p>
            <p><strong>Insufficient Evidence to Determine Net Benefits or Risks</strong>: When the evidence is insufficient to determine for or against routinely providing a service, the recommendation was graded as "insufficient evidence to determine net benefits or risks." Evidence may be conflicting, of poor quality, or lacking, and hence the balance of benefits and harms cannot be determined. Any estimate of effect that is very uncertain as evidence is either unavailable or does not permit a conclusion.</p>
            <table role="presentation" border="1" cellspacing="1" cellpadding="3" summary="Table: The American College of Physicians' Guideline Grading System">
                <thead>
                    <tr>
                        <th class="Center" valign="top" colspan="3">The American College of Physicians' Guideline Grading System*</th>
                    </tr>
                    <tr>
                        <th valign="top">Quality of Evidence</th>
                        <th class="Center" valign="top" colspan="2">Strength of Recommendation</th>
                    </tr>
                    <tr>
                        <th valign="top">&nbsp;</th>
                        <th class="Center" valign="top">Benefits Clearly Outweigh Risks and Burden or Risks and Burden Clearly Outweigh Benefits</th>
                        <th class="Center" valign="top">Benefits Finely Balanced with Risks and Burden</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td valign="top">High</td>
                        <td class="Center" valign="top">Strong</td>
                        <td class="Center" valign="top">Weak</td>
                    </tr>
                    <tr>
                        <td valign="top">Moderate</td>
                        <td class="Center" valign="top">Strong</td>
                        <td class="Center" valign="top">Weak</td>
                    </tr>
                    <tr>
                        <td valign="top">Low</td>
                        <td class="Center" valign="top">Strong</td>
                        <td class="Center" valign="top">Weak</td>
                    </tr>
                    <tr>
                        <td class="Center" valign="top" colspan="3">Insufficient evidence to determine net benefits or risks</td>
                    </tr>
                </tbody>
            </table>
            <p class="Note">*Adopted from the classification developed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) workgroup.</p>
            </td>
        </tr>
    </tbody>
</table></div>
			<h2 class="accordion-title is-active" id="507" role="tab" aria-expanded="true" aria-controls="syn507"><a href="51029.html#">Methodology</a></h2>
			<div class="accordion-panel is-active" id="syn507" role="tabpanel" aria-labelledby="507" ><table width="100%" border="1" cellspacing="1" cellpadding="8" summary="This table presents the comparison of methodology for each guideline in the synthesis.">
    <tbody>
        <tr>
            <th valign="top" colspan="2" scope="col"><em>Click on the links below for details of guideline development methodology</em> </th>
        </tr>
        <tr>
            <td class="Center" valign="top">
            <p><strong><a href="https://www.guideline.gov/summaries/summary/50887?#405" title="Guideline #11198" target="_blank">AASM</a><br />
            (2017)</strong></p>
            </td>
            <td class="Center" valign="top">
            <p><strong><a href="https://www.guideline.gov/summaries/summary/48429?#405" title="Guideline #10507" target="_blank">ACP</a><br />
            (2014)</strong></p>
            </td>
        </tr>
        <tr>
            <td valign="top" colspan="2">
            <p>The AASM and ACP clinical practice guidelines were developed from systematic reviews of the evidence. As part of the systematic review supporting the AASM guideline, original meta-analysis was performed on both diagnostic and clinical outcomes for each PICO (Population/Problem, Intervention, Comparison, Outcome) question, when possible. The ACP guideline is based on a comparative effectiveness review sponsored by the Agency for Healthcare Research and Quality (AHRQ), the 2007 Technology Assessment of Home Diagnosis of Obstructive Sleep Apnea-Hypopnea Syndrome, and an updated literature review through May 2013.</p>
            <p>Both systematic reviews provide relevant details of the literature search and selection process, including the electronic databases that were searched, time period of the search, search terms used, and the inclusion and exclusion criteria applied. To assess the quality and strength of the selected evidence, the guideline developers weighted it according to a rating scheme and provide the scheme. Both the AASM and the ACP formulated the guideline recommendations using an expert consensus process based on evaluation of the evidence, and rate the strength of the individual recommendations according to a scheme. To validate the guidelines, the ACP sought internal peer review and an independent peer review process via journal publication; the AASM sought both internal and external review.</p>
            </td>
        </tr>
    </tbody>
</table></div>
			<h2 class="accordion-title is-active" id="509" role="tab" aria-expanded="true" aria-controls="syn509"><a href="51029.html#">Benefits and Harms</a></h2>
			<div class="accordion-panel is-active" id="syn509" role="tabpanel" aria-labelledby="509" ><p><a name="source"></a></p>
<h3>Benefits</h3>
<table width="100%" border="1" cellspacing="1" cellpadding="8" summary="provides a comparison of recommendations considered by each group.">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top">AASM<br />
            (2017)</th>
            <td valign="top" style="width: 90%;">
            <ul style="list-style-type: disc;">
                <li>Use of HSAT may provide potential benefits to patients with suspected OSA. Such benefits could include convenience, comfort, increased access to testing, and decreased cost. HSAT can be performed in the home environment with fewer attached sensors during sleep. The availability of HSAT for diagnosis may improve access to diagnostic testing in resource-limited settings, or when the patient is unable to leave the home or healthcare setting for testing. In addition, HSAT may be less costly when used appropriately. </li>
                <li>The split-night protocol, in comparison to a full-night baseline assessment followed by a separate positive airway pressure (PAP) titration, has the potential to provide the needed diagnostic information and effective CPAP settings within the same recording. </li>
                <li>A second night of polysomnography in symptomatic patients allows for the diagnosis of OSA in 8% to 25% of patients with initial false negative studies. Establishing a diagnosis of OSA in these patients allows for treatment that leads to improved symptom control (e.g., less daytime sleepiness), better QOL, and potentially decreased cardiovascular morbidity over time. </li>
            </ul>
            <p>Refer to the "Benefits versus Harms" sections in the original guideline document for benefits/harms assessment of specific recommendations.</p>
            </td>
        </tr>
        <tr>
            <th width="10%" class="Center" valign="top">ACP<br />
            (2014)</th>
            <td valign="top" style="width: 90%;">
            <p>Appropriate screening and diagnosis for OSA. Evidence was mixed to correlate OSA with predictors of long-term clinical outcomes, and no causal relationships have been established.</p>
            </td>
        </tr>
    </tbody>
</table>
<h3>Harms</h3>
<table width="100%" border="1" cellspacing="1" cellpadding="8" summary="provides a comparison of recommendations considered by each group.">
    <tbody>
        <tr>
            <th width="10%" class="Center" valign="top">AASM<br />
            (2017)</th>
            <td valign="top" style="width: 90%;">
            <ul style="list-style-type: disc;">
                <li>Harms of HSAT could result from the need for additional diagnostic testing among patients with technically inadequate or inconclusive HSAT findings, or from false-positive and false-negative results leading either to unnecessary testing and treatment or to misdiagnosis and subsequent inappropriate therapy or lack of therapy. </li>
                <li>Potential disadvantages of the split-night study include insufficient diagnostic sampling (e.g., limited rapid eye movement [REM] sleep time and limited supine time in those with difficulty initiating sleep), and insufficient time to ascertain appropriate CPAP treatment settings. </li>
                <li>Routinely repeating a polysomnography in patients with an initial negative polysomnography has potential downsides. There is a risk that repeat testing could lead to false positive cases being identified, and unnecessarily treated. In addition, the routine use of a 2-night study protocol would cause inconvenience to the patient, increased utilization of resources and healthcare costs, and perhaps even delays in the care of other patients awaiting polysomnography. </li>
            </ul>
            <p>Refer to the "Benefits versus Harms" sections in the original guideline document for benefits/harms assessment of specific recommendations.</p>
            </td>
        </tr>
        <tr>
            <th class="Center" valign="top">ACP<br />
            (2014)</th>
            <td valign="top">
            <p>Evidence was mixed to correlate OSA with predictors of long-term clinical outcomes, and no causal relationships have been established.</p>
            </td>
        </tr>
    </tbody>
</table></div>
			<h2 class="accordion-title is-active" id="511" role="tab" aria-expanded="true" aria-controls="syn511"><a href="51029.html#">Abbreviations</a></h2>
			<div class="accordion-panel is-active" id="syn511" role="tabpanel" aria-labelledby="511" ><p>AASM, American Academy of Sleep Medicine</p>
<p>ACP, American College of Physicians</p>
<p>AHI, apnea&ndash;hypopnea index</p>
<p>AHRQ, Agency for Healthcare Research and Quality</p>
<p>CPAP, continuous positive airway pressure</p>
<p>ESS, Epworth Sleepiness Scale</p>
<p>GRADE, Grading of Recommendations, Assessment, Development and Evaluation</p>
<p>HSAT, home sleep apnea testing</p>
<p>OSA, obstructive sleep apnea</p>
<p>PAP, positive airway pressure </p>
<p>PAT, peripheral arterial tonometry </p>
<p>PICO, Population/Problem, Intervention, Comparison, Outcome</p>
<p>QOL, quality of life</p>
<p>RCT, randomized-controlled trial</p>
<p>REM, rapid eye movement</p>
<p>TF, Task Force</p></div>
			<h2 class="accordion-title is-active" id="512" role="tab" aria-expanded="true" aria-controls="syn512"><a href="51029.html#">Status</a></h2>
			<div class="accordion-panel is-active" id="syn512" role="tabpanel" aria-labelledby="512" ><p>This synthesis was prepared by ECRI Institute on May 25, 2017. The information was verified by ACP on June 5, 2017 and by AASM on June 12, 2017.</p></div>
	</div><!-- accordion-container -->

<!-- ASIDE -->


		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				
	<!-- About NGC -->
	<div class="info-block">
			<h3 class="info prefix-icon large-icon">About NGC Guideline Syntheses</h3>
			<p>Syntheses are systematic comparisons of selected guidelines that address similar topics. For definitions of synthesis attributes, see the 
                <a href="https://www.guideline.gov/syntheses/template">Guideline Synthesis Template</a>.    
            </p>
	</div><!-- /info-block -->
	<hr>

	<!-- New on NGC -->
	<div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
		<ul class="subscribe-links">
            <li><a href="https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss icon-feed"><span class="subscribe-links-label">RSS Feed</span></a></li>
		</ul>
	</div><!-- /.subscribable -->

	<!-- New this Week -->
	<a href="https://www.guideline.gov/new-this-week" class="block-link">
		<h4>New this Week</h4>
		<p>View more and sign up for our Newsletter</p>
	</a>

	<!-- Adobe Reader -->
	<p><a href="51029.html#" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	


</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="51029.html#" class="footer-logo">
			 		<picture>
					  	<source
					  		type="image/svg+xml"
					    	srcset="/UI/images/logo_NGC_footer.svg">
					  	<img 
						    src="https://www.guideline.gov/UI/images/logo_NGC_footer.png"
						    alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="https://www.guideline.gov/">Home</a></li>
		                <li><a href="https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://www.qualitymeasures.ahrq.gov" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/UI/images/logo_footerlink_nqmc.svg">
									<img src="https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/UI/images/logo_footerlink_hmis.svg">
								    <img src="https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="http://www.facebook.com" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="http://www.twitter.com" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="http://www.linkedin.com" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="http://www.youtube.com" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="../../../ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="https://www.guideline.gov/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
